Adamas says lead drug meets late-stage study goals

Your Health Matters

(Reuters) – Drugmaker Adamas Pharmaceuticals Inc said its lead experimental drug met the main goal of a late-stage study. The company said its drug, amantadine HCl, significantly reduced dysfunctional movement, a side effect of levodopa, a drug used to treat Parkinson’s patients. (Reporting by Vidya L Nathan in Bengaluru; Editing by Shounak Dasgupta)
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave